Immunobiology and immunotherapy in genitourinary malignancies.

@article{Tsiatas2016ImmunobiologyAI,
  title={Immunobiology and immunotherapy in genitourinary malignancies.},
  author={M. Tsiatas and P. Grivas},
  journal={Annals of translational medicine},
  year={2016},
  volume={4 14},
  pages={
          270
        }
}
  • M. Tsiatas, P. Grivas
  • Published 2016
  • Medicine
  • Annals of translational medicine
  • Immunotherapy has traditionally been a critical component of the cancer treatment armamentarium in genitourinary (GU) cancers. It has an established role in the management of carefully selected patients with metastatic renal cell carcinoma (RCC) [e.g., high dose interleukin-2 (IL-2)] and non-muscle invasive bladder cancer (NMIBC) [e.g., intravesical Bacillus Calmette-Guérin (BCG)]. In 2010, the sipuleucel-T vaccine was approved by the FDA for the management of metastatic castration-resistant… CONTINUE READING
    17 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    According to the high expression of tumor cell-associated antigen Nectin4 in patients with solid tumors such as non-small cell lung cancer, breast cancer, ovarian cancer, bladder… Expand
    ConditionsNectin4-positive Advanced Malignant Solid Tumor
    InterventionBiological
    Supportive care for patients undergoing immunotherapy
    • 29
    • Highly Influenced
    • PDF
    Immunotherapy in genitourinary cancers: where are we going?
    • 1
    Management and Supportive Care of Patients Undergoing Immunotherapy
    B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer
    • 6
    Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes
    • 5
    Immunotherapy for Prostate Cancer—Why Now?
    • 1
    Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors.
    • 10
    • PDF

    References

    SHOWING 1-10 OF 86 REFERENCES
    Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
    • R. Motzer, B. Rini, +12 authors H. Hammers
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2015
    • 712
    Prospects for the use of ipilimumab in treating advanced prostate cancer
    • 5
    Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
    • 86
    Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    • 4,063
    • PDF
    Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
    • 343
    • PDF
    Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
    • 3,173
    • PDF
    Increased survival with enzalutamide in prostate cancer after chemotherapy.
    • 3,055
    • PDF
    Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    • 1,254
    • PDF